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The search for
the Chairperson
of the Department of Surgery
continues. As you may know, Dr.
Robert Bower declined the position.
We all appreciate Walter Okunski's
dedication and commitment to the
Department of Surgery and the
institution, and thank him for agreeing
to continue as the Chairperson,
Department of Surgery, while this
search continues.
The Search Committee for the Vice
President for Clinical Services has
reviewed the· CV' s of four potential
candidates for that position. We have,
however, hired a new consultant, John
Lloyd of Witt/Kieffer, to assist us in
this important search. We will be
reviewing other potential candidates in
the next few weeks.
The search for the COO has been
progressing well. Two excellent
candidates have been identified and are
in the process of further evaluations.
Also, Michael Kaufmann, M.D., is
chairing a committee searching for the
Chairperson of Community Health and
Health Studies. This represents an
amalgam of the Research Department
and Community Health.
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Work on the PHO is moving forward
at an accelerated pace. Larry Levitt,
M.D., as Chairperson of the Care
Management Committee, has been
tackling the difficult assignment of care
management with intelligence,
industry, and enthusiasm. We see this
aspect of our managed care program as
vital to the success of our whole PHO
effort. Larry is going to need our
assistance in bringing this to fruition
and thus providing a great plan. Care
Management should be the means to
align the intereSts of the physicians and
hospital within the PHO.
Best wishes,

Ji::

Carulio, M.D.

President, M~cal Staff

At-Large Members Needed for Medical Executive
Committee
The Medical Staff Nominating
Committee is soliciting nominations for
four at-large seats, each for a threeyear term beginning July 1, 1994, on
the Medical Executive Committee.
Nominations should be submitted in
writing to John E. Castaldo, M.D.,
Chairman of the Nominating
Committee, via the Medical Staff
Services Office, Cedar Crest & 1-78,

or verbally to Joseph A. Candia,
M.D., Medical Staff President, John
Jaffe, M.D., Past President, Medical
Staff, or John W. Hart, Vice President.
All nominations must be submitted
prior to June 1, 1994.
If you have any questions regarding
this issue, please contact Dr. Castaldo
or Mr. Hart at 402-8900.

Medical Staff Services Relocates
In order to provide room for the new
ExpressCare service of the Emergency
Department, Medical Staff Services
(Cedar Crest & 1-78) was recently
temporarily relocated to the second
floor of the General Services Building.

Medical Sttiff Services - 402-9850

Individuals effected by the move
include:

Physicilln Relations Representlltives

• Joseph A. Candio, M.D.President, Medical Staff
• John W. Hart - Vice President,
Medical Staff Services
• Terri L. Kraft - Executive
Secretary
• Sally Roessler - Executive Secretary

• Rita Mest, Medical Staff
Coordinator
• Eileen Jobst, Medical Staff Secretary
• Elizabeth Ehnot, Secretary

• Patricia Skrovanek, Senior Physician
Relations Representative - 402-9859
• Maria Kammetler - 402-9857
• Janet M. Laudenslager - 402-9853
• Joseph Pilla- 402-9856

The main number for this location is

402-8900.
The remaining Medical Staff
Services/Physician Relations personnel
located in the satellite office at 1243 S.
Cedar Crest Boulevard include:

)
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Specimen Collection
CQntainers

Laboratory
Update

There have been many questions
recently regarding the preferred culture
containers in which to submit
specimens for culture. The following
are guidelines for specimen collection
container usage:
• Wounds (collected from a site
where NO fluid or tissue can be
collected)
a. Submit in a Culturette for
aerobic culture
b. Submit in a Culturette AND an
Anaerobic Specimen Collector
for an anaerobic culture
c. A Culturette is needed for each
type of culture request
e.g. 1 culturette for aerobic
culture
1 culturette for fungus
culture
1 culturette for TB
(Mycobacterial culture)

)

• Fluids
a. A fluid is PREFERABLE to a
specimen collected on a swab.
It can be concentrated to
increase the likelihood of
recovering the pathogen.
b. DO NOT PUT FLUIDS IN
CULTURETTES. Place fluids
in Port-a-cul vials for anaerobic
culture or in red top vacutainers
for aerobic culture. Wipe
rubber stoppers before
inoculating with the specimen.
NOTE: Port-a-cul vials should
be stocked by SPD in all clean
utility rooms.
c. Fluids should not be placed in
culturettes for the following
reasons:

o Culturettes are NOT leakproof containers. The specimen
can become contaminated if it
leaks out of the culturette.
How do you interpret a
Coagulase negative
Staphylococcus spp. isolated
from a fluid that was placed in
a culturette and leaked?
Contaminate or Pathogen??

o The fluid soaks into the
cotton pledget at the bottom of
the culturette trapping the
bacteria again giving erroneous
results.

o If the fluid leaks out and
contaminates the outside of the
culturette, it presents a hazard
to the person transporting the
fluid and to the technologist
working with the specimen.
• Tissues
a. Tissues are PREFERABLE to a
specimen collected on a swab.
b. Place tissues in a sterile cup and
transport immediately to
Microbiology.
Please remember culture results are
only as good as the specimen received
by the lab. Specimens must be
representative of the site of infection.
Please keep these guidelines on hand
and refer to them when there is a
question on collection and transport of
specimens. You may also refer to the
Laboratory Handbook for a complete
listing of specimens and their transport
requirements.
If you have any questions, please
contact Georgia Colasante, Supervisor,
Microbiology, at 402-8190.
Continued on Page 4
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Continued from Page 3

StwndWng ()rders
An audit conducted last summer by the

Clinical Laboratory identified an
opportunity for savings by eliminating
repetitive normal testing. Nearly all
this testing is the result of standing
orders that are not time limited, e.g.,
CBC, Chern 7 daily.
At its March meeting, the Medical
Executive Committee approved a
policy that prohibits standing orders
except where they are a part of a
clinical department-approved clinical
pathway or protocol.
This policy became effective on April
21, 1994. Thus, any orders which are
not time limited, such as CBC daily,
will result in a reminder being placed
on the patient's chart requesting that
the physician ordering the test time
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Helpful Hints
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Tmnscription
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When dictating difficult words and/or
new drugs, Transcription Services
would appreciate if you would spell
these words. This will help avoid
blank spaces in the reports.

~~~:·:~":~:~:~:::~

::::::~:•~:::::::~::::

At the time of dictation of operative
reports, please include date of surgery,
surgeons, pre-operative and postoperative diagnoses.

limit his/her order. The order, as
written, will be honored for 48 hours
to give ample time for the time
limitation to be added to the test order.
The following are examples of time
limited orders:
• CBC daily times 3
• BUN Creatinine Monday,
Wednesday, Friday while patient on
Gentamicin
• Blood cultures times 2, one hour
apart

• Chest x-ray this a.m.
Your attention and adherence to this
policy is greatly appreciated. If you
have any questions, please contact
David G. Beckwith, Ph.D.,
Administrator and Clinical Director, .
Health Network Laboratories, at
402-8157.

)

Accurate data is vital for quality
assurance, managed care contracts, as
well as reimbursement. Additions to
the list will be provided regularly to
aid in documentation.
DIAGNOSES
Hypokalemia
Dehydration

Hyponatremia
Hematuria
Urinary tract infection (UTI)
Pyuria
Urinary retention

Coding
Blood loss anemia (acute or chronic)

The following are some. common
conditions which are not consistently
documented in the medical record.

Thrombocytopenia
)

Thank you for your continued
cooperation.
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News from Research
Research Advisory
Committee - Request for

Proposals
The Research Advisory Committee
(RAC) meets bi-monthly to review
clinical/epidemiological research
proposals (requests for funding)
submitted by the Medical and
Professional staff of Lehigh Valley
Hospital.
All proposals must be submitted to the
Research Department for review three
weeks before the next scheduled RAC
meeting on June 16. All proposals
submitted by May 25 will be reviewed
by the Research Department before
being placed on the RAC agenda.

• The Harvard School of Public
Health for the Second International
Conference on Dietary Assessment to
be held on January 24, 1995 in Boston,
Mass. Submission due date is July 15,
1994.
• The Society for Medical Decision
Making for the 16th Annual Meeting to
be held on October 16, 1994 in
Cleveland, Ohio. Submission due date
is June 1, 1994.
For instructions, forms, and further
information, please contact Kathleen
Moser in the Research Department at
402-8747.

For more information or proposal
guidelines, contact James F. Reed ill,
Ph.D., Director of Research, at
402-8889.

Calls for Abstracts
A call for abstracts has been issued by
the following organizations:
• The American College of Cardiology
for the 44th Annual Scientific Session
to be held on March 19, 1995 in New
Orleans, La. Submission due date is
sq)tember 9, 1994.
• The American Society of
Nephrology for the 27th Annual
Meeting to be held on October 26,
1994 in Orlando, Fla. Submission due
date is June 24, 1994.
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News from the Office of Education
Category 2 CME
All physicians in Pennsylvania must
participate in Continuing Medical
Education (CME) activities sufficient
to (a) fulfill the requirements of the
AMA Physician's Recognition Award
(PRA), or (b) fulfill the requirements
of the Pennsylvania Medical Society.
These requirements are slightly
different, but each require participation
in a minimum of 50 hours of CME
each year, of which up to 30 hours
may be designated Category 2.
Category 2 CME activities include
clinical consultations contributing to
the physicians education, QA/QC
activities, teaching, journal clubs, self
assessment examinations and reviews,
computer based learning activities,
journal or book publications, or

attending programs designated as
acceptable for Category 2 education.
Reading medical journals is not an
acceptable activity for Category 2
designation; it is assumed that all
physicians read the medical literature
regularly.
Physicians are responsible for
cataloging their own Category 2
activities.
Only organizations accredited to give
Category 1 credit can authorize
programs to advertise that programs
fulfill the requirements for Category 2
credit. In the Lehigh Valley, the
Lehigh Valley Area Health Education
Center is accredited by the
Pennsylvania Medical Society to
approve programs for CME Category 1
credit.

New Specialty Bed Contract Signed
A new three-year specialty bed contract
waS recently signed with Kinetic
Concepts, International (KCI) which
will go into effect on June 1, 1994.
The selection of this company was
based on its ability to provide a full
line of specialty beds and specialty
mattresses which will best meet the
needs of our patients.
These specialty products are used for
patients who are at high risk for skin
breakdown, patients with stage 3 or 4
pressure ulcers who cannot be
satisfactorily positioned off of the

ulcers, and patients who are morbidly
obese who cannot be managed on our
regular hospital bed and mattress. In

addition, specialty products that
provide kinetic therapy and/or lateral
rotation are used for trauma and
critically ill patients with unstable
spines and patients who have or are at
high risk for developing pneumonia.
For more information about these
specialty products, contact Carol
Balcavage, Coordinator, Enterostomal
Therapy, at 402-8634.
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Lehigh Magnetic Imaging Center Begins Renovations
Recently, Lehigh Magnetic Imaging
Center broke ground for an expansion
and renovation project which is
expected to continue over the next
several months.
Upon completion of the construction
project, patients will be served in a
more pleasant and efficient
environment with a new entrance, new
waiting room and reception areas, a
dedicated inpatient holding area
offering privacy for those who are ill,
and an increased number of private
dressing rooms. This venture will also
include a dedicated room for the use of
pediatric patients who require a quiet
place for sedation.

In light of all the activity during
construction, patient parking has been
relocated until the project is complete.
Patients for Lehigh Magnetic Imaging
Center (LMIC) should now park in the
area directly opposite the entrance to
the 1230 and 1240 buildings. Please
note, however, LMIC patients are
cautioned not to park in the
"Handicapped Only" parking spaces
unless authorized to do so. Others will
·be ticketed.
Your cooperation in communicating
these changes to your patients is very
much appreciated.

Discount Lodging Program
A special discount lodging program has
been arranged with several area motels
for out-of-town relatives and friends of
patients at Lehigh Valley Hospital.
This program is especially directed at
visitors of hospital patients who enter
the hospital through non-routine
admissions, such as the Emergency
Department or Shock/Trauma Unit.
The following establishments have
agreed to participate in this program:
• Comfort Suites
3712 Hamilton Boulevard
Allentown

)

• Days Inn
Routes 22 and 309
Allentown

• EconoLodge
2115 Downeyflake Lane
Allentown
• The Allentown Hilton
904 Hamilton Mall
Allentown
• Holiday Inn
Fogelsville
In addition to discounted rates, some of
the establishments will provide
transportation to either hospital site.

For more information or a copy of the
brochure which describes the program,
contact Charlotte Gross, Lehigh Valley
Health Services, at 402-7450.
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Pool Trust News
At their April 8 meeting, the Dorothy
Rider Pool Health Care Trustees
agreed to provide up to $12,000 to
support four consultants to Lehigh
Valley Hospital to assist in the
recruitment process for a Chairperson
for Community Health and Health
Studies. These consultants will act as
advisors to the hospital, spending two
days each in this process, while

Congratulations!
Mark D. Cipolle, M.D., trauma
surgeon, has been named acting

helping the hospital define the roles
and activities of the evolving
Community Health function at the
hospital.
The search committee is chaired by
Michael W. Kaufmann, M.D.,
Chairperson, Department of
Psychiatry.

Thomas D. Meade, M.D., orthopedic
surgeon, recently set two personal best
free-style records and was a member of
a record setting 200 yard free-style
relay at The Mastors Swim
Championship meet held recently at
Rutgers University.

medical director of flight operations
(University MedEvac). George E.
Moerkirk, M.D., will remain in the
role as chief of the Division of PreHospital Emergency Medical Services.
In this capacity, he will continue to
provide training to pre-hospital
personnel and represent the hospital on
the Emergency Medical Services
Council.

Division of Endocrinology/Metabolism, )
was recently inducted as a Fellow in
the American College of
Endocrinology at the annual meeting in
New Orleans, La.

Tx~,

Michael D. Pasquale, M.D., trauma

a portable oxygen unit
developed by Peter H. Goldman,
M.D., family practitioner, has been
selected by the National Safety
Council's Lifeguard Training Program,
and will be used for instruction in its
Supplemental Oxygen Support (SOS)
course. The SOS course was
developed around this product which is
currently being used by many aquatic
facilities, including Wildwater
Kingdom.
Michael W. Kaufmann, M.D.,

Chairperson, Department of
Psychiatry, was recently nominated by
the Lehigh Valley Psychiatric Society
as Councilor at Large.

LaiTy N. Merkle, M.D., chief,

surgeon, was appointed Medical
Director for the Trauma Transitional
Unit (TTU), formerly 5A, at Cedar
Crest & I-78. In this position, he will
work with the nursing staff,
technicians, therapists, and physicians
utilizing the unit to develop standards
and protocols aimed at promoting the
highest quality care. He will also head
an educational program for the TTU
staff.
Barry A. Ruht, M.D., orthopedic
surgeon, waS recently elected a Fellow
in the American Academy of
Orthopaedic Surgeons.
)
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Publications, Papers and Presentations

}

Indru T. Khubchandani, M.D., colon
and rectal surgeon, was invited to
parpcipate in the Third Biennial Course
and International Meeting of the
Coloproctology in Ivrea (Torino), Italy
from March 24-26. Dr. Khubchandani
chaired a session on Complicated
Problems in Colon and Rectal
Surgery and presented actual case
reports to a panel of professors and
chairmen of departments of Colon and
Rectal Surgery from various countries
including Sweden, Brazil, Denmark,
Italy, England, and Egypt. He also
chaired a panel on Minimally Invasive
Surgery.

Meniscectomy Relative to the Acutely
Meniscectomized Joint: A
Mechanical Study in the Goat, which
was published in the Jou17Uil of

Later in the week, Dr. Khubchandani
lectured at the University of Genoa,
Italy, and spoke about The Options
for Removal of Rectal Cancer by
Less Than Conventional Radical
Procedures. He also lectured at the
University of Catania in Sicily where
he spoke about Performance of
Anorectal Surgery in Ambulatory
Fashion. The final stop was at
Syracuse, Sicily, where Dr.
Khubchandani detailed the progress in
colorectal surgery, including
endoscopic and laparoscopic
procedures.

Charles J. Scagliotti, M.D., general/
trauma surgeon, presented a case
report on Appendiceal Cancer
Treated Laparoscopically at the
annual meeting of the Society of
Laparoendoscopic Surgeons held
recently in Orlando, Fla. Also at the
meeting, Clark Gerhart, M.D.,
surgical resident, presented his paper,
Technique for Laparoscopic Vertical
Banded Gastroplasty, which was coauthored by Peter F. Rovito, M.D.,
general surgeon. They have submitted
their paper for publication to the

Thomas D. Meade, M.D., orthopedic
surgeon, recently presented Ob, My
Aching Back during a free public
lecture sponsored by the Health
Promotion and Disease Prevention
Department and the Chronic Disease
Education Committee of Lehigh Valley
Hospital.

preliminary data on Open versus
Laparoscopic Colon Resection: Are
Specimens the Same? Richard C.
Boorse, M.D., general surgeon, is coinvestigator of this ongoing study.

Orthopaedic Research, The Jou17Uil of
Bone and Joint Surgery, Inc., Volume
11, 1993, pp. 796-804.
George M. Perovich, Ed.D.,
psychologist, presented Exposure to
Toxins: Use of Neuropsychological
Tests in Conjunction with Other
Diagnostic Techniques at the
American College of Forensic
Psychology lOth Annual Symposium
held May 12-15 in Montreal, Canada.

Jou17Uil of the American College of
Surgeons. Dr. Gerhart also presented

Dr. Meade also co-authored an article,
Knee Joint Contact Pressure
Decreases After Chronic
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Upcoming Seminars, Conferences and Meetings
Regional Symposium Series V
Obstetrics and Gynecology - Joseph
A. Miller, M.D. Resident Research
Day will be held on Friday, June 10,
from 8 a.m. to 4:20p.m., in the
Auditorium of Lehigh Valley Hospital,
17th & Chew.
Obstetricians, gynecologists, family
practitioners, nurses, residents,
students, and other health care
professionals interested in an update in
obstetrics and gynecology will benefit
from this program.
At the completion of the program,
participants should be able to:
• describe signs and symptoms,
diagnosis, and treatment for urinary
incontinence; and
• discuss current treatment modalities
for hypertensive disorders in
pregnancy.

For more information, please contact
Human Resource Development at 4024609.

Ethics Committee Program
CPR and DNR: Have We Got the
Cart Before the Horse?, a spirited
discussion sponsored by the Ethics
Committee, will be held on Thursday,
May 26, at noon, in the Auditorium of
Lehigh Valley Hospital, Cedar Crest &
1-78.
Presenters include Kevin J. Farrell,
M.D., trauma/general surgeon;
Alexander D. Rae-Grant, M.D.,
neurologist; and Stephen E. Lammers,
Ph.D., Ethics consultant.
For more information, contact Gale
Brunst in the Critical Care Office at
402-8450.

Medical Grand Rounds
Chronic Fatigue Syndrome will be
held on Saturday, June 11, from 7:30
a.m. to 12:30 p.m., in the Auditorium
of Lehigh Valley Hospital, Cedar Crest
& 1-78.
Physicians, nurses, and other health
care professionals concerned with
chronic fatigue syndrome will benefit
from the program.
At the completion of the program, the
participant should be able to:
• diagnose and manage patients with
chronic fatigue syndrome;
• discuss new insights related to this
disbrder; and
• have a more comprehensive clinical
approach to patients with fatigue.

Transplantation in the Lehigh Valley
- An Update will be presented by
Craig R. Reckard, M.D., chief,
Section of Transplantation Surgery, on
Tuesday, May 31, at noon in the
Auditorium of Lehigh Valley Hospital,
Cedar Crest & 1-78.
The Medical Grand Rounds Video
Series may be borrowed from the
Department of Medicine at Cedar Crest
& 1-78. Physicians who watch these
tapes may claim one hour of Category
2 CME credit.
For more information or to arrange
viewing of a video, contact the
Department of Medicine at 402-8200.
Page 10
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Department of Pediatrics
Puzzling Cases for the Professor will
be presented by Patrick Pasquariello,
M.D., Director, Diagnostic Center,
Children's Hospital of Philadelphia, on
Friday, May 20.
Hemolytic Uremic Syndrome will be
presented by Mary Moran, M.D.,
Diagnostic Referral Center, St.
Christopher's Hospital for Children, on
Friday, June 3.
DDAVP will be presented by Richard
Caesar, M.D., Urology Section, St.
Christopher's Hospital for Children, on
Friday, June 17.
The above Pediatric conferences will
begin a noon in the Auditorium of

• For Sale or Lease - Springhouse Professional
Center, 1575 Pond Road. Ideal for physician's
office. Approximately 1,000 sq. ft.
• For Sales or Lease -- Medical/ Professional threestory office building at 1730 Chew Street,
Allentown. Excellent condition with recent
renovations. Approximately 8,800 sq. ft. for single
or multiple specialty practice. Includes long-term
parking lease at Fairgrounds. Potential telephone
and dictations systems.
• For Sale - Office building at Northeast corner of
19th and Turner Streets in Allentown. Upper level 2,400 + sq. ft., large waiting room, two large
consultation rooms, five exam rooms, etc. Lower
level - 2,300 + sq. ft. Parking Jot for 18 oars.
• For Lease - Office to sublet on Monday, Tuesday,
Thursday, and Friday. 950 sq. ft. Common waiting
area. Lakeside Professional Building, Quakertown.
• For Lease -- Monday time slot available in the
medical office building on the campus of Gneden
Huetten Memorial Hospital in Lehighton.
• For Lease- Large, newly remodeled, completely
furnished medical office space available for
subleasing/time share at Cedar Crest Professional
Park. Top of the line telephone system.
Transcription and computer system with electronic
billing available.

Lehigh Valley Hospital, 17th & Chew.
For more information, contact Beverly
Humphrey in the Department of
Pediatrics at 402-2410.

Psychiatric Grand Rounds
Chronic Pain and the Disability
Epidemic will be presented by Gerald
Aranoff, M.D., Associate Clinical
Professor, Tufts Medical School, and
Director, Boston Pain Center, on
Thursday, May 19, from noon to 1
p.m., in the Auditorium of Lehigh
Valley Hospital, 17th & Chew.
As lunch will be provided, preregistration is requested by calling the
Department of Psychiatry at 402-2810.

• For Lease -- Slots are currently available for the
Brown Bag suite at Kutztown Professional Center.
Ideal for satellite location.
• For Lease - Medical-professional office space
located on Route 222 in Wescosville. Two 1 ,000
sq. ft. offices available or combine to form larger
suite.
• For Lease - Medical office space located in
Peachtree Office Plaza in Whitehall. One suite with
1,500 sq. ft. (unfinished - allowance available), and
one 1,000 sq. ft. finished suite.
• For Lease - Specialty practice time-share space
available in a comprehensive health care facility.
Riverside Professional Center, 4019 Wynnewood
Drive, Laurys Station. Half- or full-day slots
immediately available.
• For Lease - Professional office space available in
an established psychology and psychotherapy
practice at 45 North 13th Street, Allentown. Large,
warm Victorian building in a relaxed atmosphere.
Secretary and billing available and included in some
leases. Furnished or unfurnished full offices and
sublets available. Utilities included.
For more information or for assistance in finding
appropriate office space to meet your needs,
contact Joe Pilla, Physician Relations Rep, at
402-9856.
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WHO'S NEW

The Who's New section of Medical
Staff Progress Notes contains an
update of new appointments, address
changes, newly approved privileges,
etc. Please remember that each
department or unit is responsible for
updating its directory, rolodexes, and
approved privilege rosters.

Medical Staff
Appointment
Michael J. Greenberg, MD
Radiation Medicine Associates
Pocono Cancer Center
231 E. Brown Street
East Stroudsburg, P A 18301
(717) 476-3488
Department of Radiation Oncology
Provisional Consulting
Susan J. Kucirka, MD
Riverside Dermatology Associates
(Terry I. Robbins, MD)

Riverside Professional Center
Route 145 Box P
Laurys Station, PA 18059
(610) 261-1115
Department of Medicine
Division of Dermatology
Provisional Referring

Bentley A. Ogoke, MD
Lehigh Valley Pain Management
(Yasin N. Khan, MD)

1251 S. Cedar Crest Blvd.
Suite 102B
Allentown, PA 18103
(610) 402-8216
Department of Anesthesiology
Provisional Active

Judith R. Pryblick, DO
(solo)
1901 Hamilton Street
Suite 2
Allentown, PA 18104
(610) 437-7181
Department of Family Practice
Provisional Referring

Bernard D. Servagno, DMD
(solo)
623 W. Union Blvd.
Suite 3
Bethlehem, PA 18018
(610) 882-9910
Department of Dentistry
Division of Prosthodontics
Provisional Active

Additional Privileges

J. Patrick Kleaveland, MD
Department of Medicine
Division of Cardiology
Active
Transluminal Extraction Catheter
Atherectomy (TEC)

Edward M. Mullin, Jr., MD
Department of Surgery
Division of Urology
Active
Collagen Implantation Privileges
Margaret S. Tretter, DO
Department of Medicine
Division of General Internal Medicine
Provisional Active
Swan-Ganz Catheter Placement

Change of Status
David D. Marvl, MD
Department of Psychiatry
Ftom Courtesy to Emeritus Courtesy
Page 12
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Practice Change

New Fax Number

William S. Berg, DPM
No longer associated with East Penn
Podiatry Associates

Deparbnent of Famlly Practice
Headley S. White, Jr., MD
William L. Miller, MD
Barbara Salvadore
Marcia Shaffer
Karen Nodoline
(610) 402-8489

)

A~dress

and Telephone
Number Changes
WilliamS. Bera, DPM
Fleetwood Medical Center
P.O. Box 425
805 N. Richmond Street
Fleetwood, PA 19522
(610) 944-6537
Howard E. Hudson, Jr., :MD
Fairgrounds Anesthesia Associates, PC
400 N. 17th Street, Suite 205
Allentown, PA 18104
(610) 821-0750
(610) 821-9099- FAX

Allied Health
Professionals
.Resignation
Beth· L. Rominger, PA-C

Physician Extender
Physician Assistant
(Panebianco-Yip)

Martin D. Misenhimer, :MD
5300 KidsPeace Drive
Orefield, PA 18069
(610) 799-8000

)
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Guidelines on Preadmission Testing of Elective Surgery Patients Without Significant
Underlying Disease

As a component of our review of clinical utilization of testing, we have identified preadmission testing of
elective surgical patients as an opportunity where we can reduce costs and not adversely effect prudent patient
management. We hope to limit unnecessary testing of young healthy patients while meeting the standards set by
KePRO for elective surgery patients. We are aware that some testing is a result of KePRO citations in the past
and have reviewed requirements set by KePRO as well as published "industry" standards used at other tertiary
care hospitals. We believe that by establishing a hospital advisory, we will set a standard for reference should
KePRO question a decision.

The recommendation below is a combination of protocols and standards from the University of Chicago
(Roisen), Mayo Clinic, and KePRO for elective surgery patients without significant underlying disease.

AGE/MALE
X-ray

Hgb
Neonates

ECG

X

Age <40
Age40-49

±

Age 50-64

X

Age

~65

±

X

X

AGE/FEMALE
Hgb
Neonates ( <6mo.)

X

Age <40

±

Age 40-49

±

Age 50-64

X

Age

~65

X

(± -

use clinical judgement)

X-ray

ECG

X

±

X
Page 14

Page 2
These recommendations apply to patients undergoing all anesthetics: general, regional or blocks, and local with
sedation.
If you order one of these studies, the folloWing time frames prior to surgery apply:
Hemoglobin - Within 1 month. Not required for patients under 49 years old with local anesthesia.
ECG - Within 12 months; within 3 months for cardiovascular disease.
X-ray -Not required on healthy patient. Within 1 month for patients with respiratory or cardiovascular
disease.
Documentation of test results from a CLIA certified lab should exist in the chart, but testing at laboratories
other than Lehigh Valley Hospital need not be repeated.
Also, please remember to try to schedule all elective surgery PAT more than 72 hours prior to admission since
work performed within 72 hours of admission is rolled into the DRG hospital expense for medicare patients.

DGB:tjw
c: \wp51 \memo94\clindept.l
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Improving the Diagnostic Efficiency of Laboratory
Tests
In last month's newsletter, we introduced
the concepts of diagnostic sensitivity (the
likelihood a test will be positive in a
patient with the disease) and specificity
(the negativeness of a test in a patient free
of the disease). These concepts were used
to evaluate the performance of the newly
introduced mass molecule CKMB test.
Also discussed was how these concepts
were used to establish a reference range
for this MCKMB test. In this issue, the
interrelationship between sensitivity and
specificity will be compared and then used
to show how the diagnostic efficiency of a
laboratory test can be improved by the
physician.

a MI and some would not have had a MI.
It is impossible to select a cutoff reference
interval for the MCKMB test that would
afford complete discrimination between the
two groups. At any reference range one
must sacrifice sensitivity for specificity and
vice-versa. Herein lies the major shortfall
of laboratory diagnosis because few tests
are sensitive and specific at the same time.
Looking at the results of multiple
laboratory tests improves predictive value
somewhat, but the trade off between
sensitivity and specificity always remains.
There are no perfect tests or combination
of tests with 100% sensitivity and 100%
specificity. An example of how they are
related is shown in the following table
which demonstrates this inverse
relationship between sensitivity and
specificity.

If one studied patients admitted to the
coronary care unit with the diagnosis of
MI based on history, EKG findings and
MCKMB results, some would have

ENZYME TEST
Prevalence of MI SO%
Reference
Value

Sensitivity %

Specificity %

Predictive Value
Positive Test %

2

100

60

71

4

95

75

79

6

85

85

85

8

70

95

93

10

50

100

100
Page 16

The type of disease being diagnosed by a
test determines whether it is desirable to
maximize sensitivity or specificity. A
clinician who obtains a history and
physical should be able to have a combined
sun of sensitivity and specificity of~
to 170% for the diagnosis of most
diseases. This means that the laboratory
test that is ordered to diagnose the disease
should perform better than 170% if it is to
be used for a diagnosis and not just for
confirmation of the diagnosis.

MI the remaining 50% would be false
positives. This same enzyme test used in
the CCU exhibits a predictive value of
95% with only 5% of the positive test
results being false positives.

Finally, the following table demonstrates
the change in predictive value that occurs
for a test with changing prevalence of
disease. It can be readily seen that a
particular test has a higher predictive value
when the disease occurs with a higher
prevalence. This explains why a ~
diagnostic test frequently fails as a
screening test. When clinical judgment is
used in ordering laboratory tests, the
patient, suspected of having a particular
disease, is placed in a new population with
a high prevalence or probability of disease.
This concept is shown in the table below.

For tests used in screening for a disease
(i.e., neonatal metabolic screening & HIV)
the predictive value is low as is the sum of
sensitivity plus specificity. Therefore the
performance of the test is poor. By
employing these predictive value concepts
we can set ~ur testing parameters for the
screening test to maximize sensitivity.

Predictive value as a function of disease
prevalence for a test with 95% sensitivity
and 95% specificity.

It is apparent from the above discussion
that a physician can significantly improve
the diagnostic performance of a laboratory
test with a good history and physical that
places the patient in a category with higher
probability of disease.

This means that all patients with the
disease test positive but so do a number of
patients who are !liB gositives. A second
confirmation test designed to maximize
specificity is used to separate the true
positives from the false positives.
However this is not without additional cost
to the medical system.

Prevalence of Disease %

Predictive Value of a Positive Test

1

16

2

28

5

50

15

77

25

86

50

95

If this test were the MCKMB test for the
diagnosis of a MI, we can compare the
performance of this test in the chest pain
clinic (5% prevalence of MI) to that in the
coronary care unit (50% prevalence of
Ml). When used in the clinic 50% of the
patients with a positive test would have a

In summary, the statistical discussion of

testing as presented in the last three
newsletters suggests there is no free lunch
when it comes to laboratory testing. All
criteria pertaining to a test must be
identified and maximized to ensure the
correct diagnoses of a specific disease
state.
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P & T HIGHLIGHTS
The following action were taken at the April 11, 1994 Pharmacy and
Therapeutics Committee Meeting - James A. Giardina, Director of Pharmacy

FORMULARY ADDITION REQUESTS
AFFECTING THE BRAIN
Risperidone (Risperdal, Janssen) is a
mixed serotonin-dopamine antagonist
which is approved for the treatment of
psychotic disorders. At low doses
resperidone is a selective serotonin 5HT[2] receptor antagonist while at higher
doses it antagonizes dopamine-D[2]
receptors. As a central dopamine-D[2]
antagonist, it is less active than
haloperidol. Risperidone was developed on
the hypothesis that combining both
serotonin and dopamine receptor inhibition
would result in an improved therapeutic
response in schizophrenia. It is hoped that
it will improve both positive and negative
symptoms in psychotic patients without
significant extrapyramidal symptoms. At .
low doses, it is thought to be effective in
schizophrenic patients with predominantly
negative symptoms, while at higher doses,
it exerts activity on both positive and
negative symptoms.
Risperidone is well absorbed and
bioavailability is unaffected by food. It
undergoes extensive hepatic metabolism
via the cytochrome P450-IID6 System to
an equally active metabolite. The
combined products have an elimination
half-life of 20 hours and are excreted
without further degradation; hence,
clearance is reduced in renally impaired as

well as elderly patients. 9% of patients in
clinical trials had therapy discontinued due
to side effects, which are dose related and
more likely when daily doses exceed 6mg.
The most frequently reported ones were
extrapyramidal reactions, nausea,
dizziness, hyperkinesia, somnolence,
constipation and rhinitis. A transient
decrease in blood pressure and heart rate,
postural hypotension, and syncope have
been reported, especially during the initial
dose titration period. Both risperidone and
its metabolite appear to lengthen the QT
''interval in some patients and may increase
the risk of torsades de pointes, particularly
in patients with bradyc~rdia, electrolyte
~m.balance, or in patients on drugs that
prolong the QT interval. Drug interactions
include agents such as quinidine, which
interferes with cytochrome
P450-IID6 metabolism and interferes with
the conversion to the metabolite.
Risperidone is unlikely to interfere with
other agents metabolized by the
cytochrome P450-IID6 system due to its
weak affinity for the enzyme. Chronic
administration of carbamazepine may
increase the clearance of ·risperidone while
chronic clozapine therapy may reduce the
clearance. It may enhance the effects of
some hypotensive agents and may
antagonize the effects of levodopa and

)
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dopamine agonists. It should be' used
cautiously with other centrally active
agents and alcohol.
It is recommended that therapy begin at
1mg twice daily with a 1mg twice daily
increase on days 2 and 3. Further dosage
adjustments of 1mg twice daily are
recommended at weekly intervals with the

Venlafaxine (Effexor, Wyeth) is a bicyclic
antidepressant that inhibits neuronal uptake
of serotonin, norepinephrine, and to a
lesser extent, dopamine. It is indicated for
the treatment of depression. Its selectivity
is serotonin > norepinephrine >
dopamine. Animal studies predict a more
rapid onset of action than tricyclic
antidepressants.
Venlafaxine is well absorbed with food
having no effect on absorption, it is
rapidly converted via a saturable metabolic
pathway (first-pass effect) to an active and
other metabolites. No other metabolism
occurs prior to excretion in the urine.
There are few studies available to date
showing efficacy as compared to other
antidepressants. Adverse effects include
anorexia, dizziness, blurred vision and
sexual dysfunction. Many are dose related
and largely due to serotonin activity.
Tachycardia and hypertension have been
reported and routine blood pressure
monitoring is recommended with dosage
reduction/ discontinuation recommended in
patients with sustained, increased blood
pressure.

maximum· recommended dose being 6mg
twice daily. Dose initiation, adjustment
and maximum are halved in elderly and
debilitated patients, patients with severely
impaired renal or hepatic status, and
patients predisposed to hypotension.
Risperidone comes as 1, 2, 3 and 4mg.
Annual costs of therapy are projected at
$1900-2400.

Little information is available about
specific interactions with a
recommendation to avoid concomitant or
therapy within 14 days of MAO inhibitors.
Use of other antidepressants is not
encouraged and concurrent CNS
depressants may result in additive or
synergistic sedation. Venlafaxine has not
been studied in pregnancy, lactation or
children. The initial dose is recommended
as 75mg daily in two or three divided
doses. Incremented adjustments of
75mg/day are recommended at 4 day
intervals to a total of 225mg. The
maximum recommended dose in severely
· depressed patients is 375mg/day. Dosage
reduction is recommended in hepatically
and renally impaired patients. In
hemodialysis patients, the dose should be
reduced by 50% and withheld until after
dialysis. Venlafaxine comes as 25, 50, 75
and lOOmg tablets. Venlafaxine was
added for a 6 month therapeutic evaluation
to see if it does have a quicker onset of
activity as well as whether it will lessen
the need for augmentation therapy because
of its unique pharmacologic profile.

)
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Pergolide (Permax, Lilly) is a semisynthetic ergot alkaloid which is stated to
be more potent and longer acting than
bromocriptine. It is indicated as an
adjunct to traditional therapy in
Parkinson's Disease and may offer value
in preventing, reducing or treating
fluctuating or "on/off" response. It is a
centrally acting dopamine agonist which
stimulates both D 1 and D2 receptors.
Once converted to dopamine, levodopa
stimulates both D1 and D2 receptors,
whereas bromocriptine stimulates only D2 .
receptors.
Oral absorption is rapid and followed by
extensive first-pass metabolism to many
active metabolites, which are excreted in
the urine (55%), feces (40%) and lungs
(5%). It has a duration of action of
greater than 24 hours. The most common
adverse reactions to pergolide are nausea,
light-headedness, dry mouth, drowsiness,
orthostatic hypotension, confusion,

hallucinations and dyskinesias. Side
effects are dose related as with the other
anti-parkinson agents. In patients taking
pergolide who are able to reduce levodopa
dosage, side effects may be decreased.
Caution should be exercised in patients
prone to dysrhythmias.
Pergolide has not been studied in
pregnancy, lactating women or children.
Dopamine antagonists (neuroleptics,
metoclopramide) may diminish its activity.
Dosage should be started at 0.05mg for the
first 2 days with escalation by 0.10.15mg/day every 3rd day over the next
12 days. Doses may then be adjusted by
0.25mg/day every third day until
therapeutic response is achieved. The
average therapeutic dose is 3mg with an
average concurrent daily dose of
levodopa/carbidopa of 650mg (as
levodopa). Pergolide comes as 0.05, 0.25
and 1mg tablets.

DRUG USE EVALUATION (Dl!E) CORNER
INJECTABLE H2RA USE
Pharmacy presented the most recent 7
month report together with the full year's
report on converting IV H2RAs to PO.
The study focused on patients who were
currently receiving at least two scheduled
(not PRN) medications orally and
recommendations for conversion to the PO
route. 91% of the conversion
recommendations were followed during the
last 7 months. Due to the nature of the
study, there was an inherent

lag time from Pharmacist recommendation
to Physician action with results showing
that 50% were changed in 1 day, 75 % in 3
days, and 91% in 5 days. Given the rate
of acceptance, and the potential savings
involved, the Committee approved
automatic conversion of Famotidine IV to
Nizatidine PO for patients who have
received and tolerated at least 2 oral meds
for a minimum of 24 hours. The tentative
start date for the automatic conversion of
IV to H2RAs to PO will be June 1, 1994.
)
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ALTEPLASE REVIEW
A comprehensive review of Alteplase (t-PA) prescribing from May 93 to March 94 was
performed to assess therapy complications. 91 of 92 patients received either standard or
accelerated dosing.
Table 1 -Review of 91 patients tPA (May 93 - March 94)
# of Patients (%)
Standard
Number of patients
Patients L. 75 y.o.

54 (59%)

# of Patients (%)
Accelerated
37 (41 %)

2

5

2

5

No bolus

12 (22%)

4 (11 %)

5,000 unit bolus

38 (78%)

28 (76%)

1 (2%)

5 (14%)

with tPA

36 (67%)

29 (78%)

after tPA

18 (33%)

8 (22%)

Fatal intracerebral bleed (1 %)

0

1

All Intracerebral bleeds (4%)

1

3

Non-hemorrhagic stroke (0%)

0

0

Recurrent ischemia ( 10%)

7

2

Other bleeding (13%)

5

7

Patients requiring transfusion (9%)

4

4

Patients

< 65 Kg

Heparin Use
Dose

> 5,000 unit bolus
Timing

Adverse Clinical Events
(% incidence of total# patients)

Number patients (%) requiring further cardiac interventions
PTCA

22 (41 %)

13 (35%)

CABG

9 (17%)

5 (14%)

}
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The two dosing regimens are defined as follows:

Standard Dosing Regimen
Patient weight 2. 65Kg

lOOmg

Patient weight < 65 Kg

1.25mg/Kg

Bolus over 1-2min

6-10%

6mg

Total over next 58-59 min

54-50%

54mg

Total over second hour

20%

20mg

Total over third hour

20%

20mg

Usual Dose
for a 70Kg
Patient

Accelerated (Front loaded) Dosing Regimen from GUSTO Trial
Patient weight 2. 65Kg
Patient weight

< 65Kg

Bolus

lOOmg
Weight adjusted dose
15mg

Usual Dose
for a 70Kg
Patient
15mg

total over first 30 min

0.75mg/Kg (not to
exceed 50mg)

50mg

total over next 60 min

0.35mg/Kg (not to
exceed 35mg)

35mg

pt\41194.min

Page 22

